|1.||Steventon, Glyn B: 4 articles (02/2010 - 12/2004)|
|2.||Di Vincenzo, Serena: 3 articles (03/2014 - 11/2013)|
|3.||Gjomarkaj, Mark: 3 articles (03/2014 - 11/2013)|
|4.||Ferraro, Maria: 3 articles (03/2014 - 11/2013)|
|5.||Gerbino, Stefania: 3 articles (03/2014 - 11/2013)|
|6.||Lanata, Luigi: 3 articles (03/2014 - 11/2013)|
|7.||Pace, Elisabetta: 3 articles (03/2014 - 11/2013)|
|8.||Chalumeau, Martin: 3 articles (01/2013 - 01/2009)|
|9.||Mitchell, Stephen C: 3 articles (02/2010 - 11/2006)|
|10.||Duijvestijn, Yvonne C M: 2 articles (01/2013 - 01/2009)|
|1.||Chronic Obstructive Pulmonary Disease (COPD)
10/01/2010 - "These results suggest that carbocysteine may be beneficial in patients with COPD by increasing the clearance of bacteria and decreasing bacterial load."
11/25/2013 - "Carbocysteine, an anti-oxidant and mucolytic agent, is effective in reducing the severity and the rate of exacerbations in COPD patients. "
11/01/2013 - "Carbocysteine, an antioxidant and mucolytic agent, is effective in reducing the severity and the rate of exacerbations in COPD patients. "
03/01/2009 - "Carbocysteine has been recently recognized as an effective and safe treatment for the long-term management of COPD, able to reduce the incidence of exacerbations and improve patient quality of life. "
10/01/2010 - "Several clinical trials have indicated that carbocysteine reduces exacerbation rates in COPD. "
|2.||Otitis Media with Effusion
05/01/2006 - "Efficacy of S-carboxymethyl-L-cysteine for otitis media with effusion."
07/01/1994 - "Effect of S-carboxymethylcysteine on the clearance of middle ear effusion. "
01/01/2001 - "Studies were randomised, double-blind comparisons of S-carboxymethylcysteine (any dose and duration) with placebo in otitis media with effusion. "
01/01/1988 - "We carried out a double blind comparative trial with placebo serving as control using 250 cases of infant otitis media with effusion (OME) in order to objectively evaluate the clinical usefulness of S-carboxymethylcysteine (S-CMC), an oral mucolytic agent, against OME. "
08/01/2000 - "The role of Mucodyne in reducing the need for surgery in patients with persistent otitis media with effusion."
|3.||Obstructive Lung Diseases (Obstructive Lung Disease)
01/01/2008 - "The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease."
02/19/2010 - "All these results indicate that the oral administration of S-carboxymethyl-L-cysteine may be useful during the therapeutic management of chronic obstructive pulmonary disease in dogs."
01/01/1997 - "S-carboxymethylcysteine (S-CMC) has been shown to directly enhance the ciliary activity of the chronic sinusitis mucosa. "
09/01/1993 - "Effect of S-carboxymethylcysteine on ciliary activity in chronic sinusitis."
08/01/1985 - "[Effects of carbocysteine on experimental chronic sinusitis caused by long-term exposure to SO2]."
01/01/1997 - "Since s-carboxymethylcysteine (S-CMC) can directly enhance the ciliary activity in the maxillary sinus mucosa of patients with chronic sinusitis in the absence of significant organic changes of ciliated cells, the nebulization therapy using this medicine might be more effective in the treatment of chronic sinusitis than oral administration of the medicine. "
09/01/1992 - "Ancillary therapies of sinusitis could be directed toward (1) preventing viral upper respiratory tract infections (immunizations, virucidal-impregnated tissues, and proper hand-washing techniques); (2) blocking rhinoviral replication and suppressing mediator release with supraphysiologic nasal hyperthermia, although contradictory studies exist with regard to efficacy; (3) promoting sinus and nasal ventilation with both topical and oral alpha-agonists and exercise; (4) improving mucociliary clearance by reducing mucus viscosity and elasticity with saline solution irrigation, mucoregulators (N-acetylcysteine, S-carboxymethylcysteine, and iodinated glycerol), and ciliary stimulants (adenosine triphosphate); and (5) suppressing/modulating cellular inflammation (eosinophilic, basophilic, and neutrophilic) with topical nasal corticosteroid sprays and mediator antagonists. "
|5.||Lung Diseases (Lung Disease)
01/01/1988 - "In the present study the "spinnability" parameter was included in the functional tests aimed at evaluating the efficacy of the carbocysteine-sobrerol combination in 16 patients suffering from chronic abstructive lung disease with bronchial hypersection. "
01/01/2013 - "The objective was to assess the efficacy and safety and to establish a benefit-risk ratio of acetylcysteine and carbocysteine as symptomatic treatments for acute upper and lower RTIs in paediatric patients without chronic broncho-pulmonary disease. "
01/01/2009 - "The objective was to assess the efficacy and safety and to establish a benefit-risk ratio of acetylcysteine and carbocysteine as symptomatic treatments for ARTIs in children without chronic broncho-pulmonary disease. "
01/01/1988 - "[Comparative evaluation of the effectiveness of lasolvan and mucodine in chronic nonspecific lung diseases]."
01/01/2013 - "Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease."